| 2023-08-22 |
详情>>
股本变动：
变动后总股本433.59万股
|
| 2023-08-22 |
详情>>
业绩披露：
2023年中报每股收益-0.06美元,归母净利润-30.37万美元,同比去年增长44.40%
|
| 2023-06-16 |
股东大会：
将于2023-06-30召开股东大会
会议内容 ▼▲
- 1.A proposal to amend (the “Charter Amendment”) Monterey Innovation’s amended and restated certificate of incorporation, as amended (the “charter”), by allowing us to further extend the date by which we have to consummate a business combination (the “Combination Period”) from July 5, 2023 to up to nine (9) times by an additional month each time (or up to April 5, 2024) (as extended, the “Extended Date”) by depositing into the trust account $100,000 for each additional month extension;
2.A proposal to amend (the “Trust Amendment” and together with the Charter Amendment, the “Extensions”) the Investment Management Trust Agreement, dated September 30, 2021, as amended, by and between Continental Stock Transfer & Trust Company and Monterey Innovation (the “trust agreement”), allowing us to extend the Combination Period from July 5, 2023 to the Extended Date by depositing into the trust account $100,000 for each additional month extension;
3.A proposal to direct the chairman of the special meeting to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Charter Amendment Proposal and the Trust Amendment Proposal or the Board determines before the special meeting that it is not necessary or no longer desirable to proceed with the Charter Amendment Proposal and the Trust Amendment Proposal.
|
| 2023-05-18 |
详情>>
业绩披露：
2023年一季报每股收益-0.03美元,归母净利润-15.23万美元,同比去年增长57.40%
|
| 2023-04-17 |
详情>>
业绩披露：
2022年年报每股收益-0.11美元,归母净利润-127.39万美元,同比去年增长-118.42%
|
| 2023-03-09 |
详情>>
内部人交易：
NORTHSTAR BIO VENTURES, LLC等共交易5笔
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.07美元,归母净利润-96.68万美元,同比去年增长-466931.4%
|
| 2022-09-08 |
股东大会：
将于2022-09-29召开股东大会
会议内容 ▼▲
- 1.Proposal No. 1 - The Charter Amendment Proposal – a proposal to amend (the “Charter Amendment”) Monterey Bio’s amended and restated certificate of incorporation (the “charter”) by allowing us to extend (the “Extension”) the date by which we have to consummate a business combination (the “Combination Period”) for an additional three (3) months, from October 5, 2022 (the date which is 12 months from the closing date of our initial public offering of our units (the “IPO”)) to January 5, 2023, by depositing into the trust account (the “trust account”) $350,000 (the “Extension Payment”) for the three-month extension, and thereafter to extend the Combination Period up to six (6) times by an additional month each time (or up to July 5, 2023) by depositing into the trust account $120,000 for each additional month extension;
2.Proposal No. 2 - The Trust Amendment Proposal – a proposal to amend (the “Trust Amendment” and together with the Charter Amendment, the “Extensions”) the Investment Management Trust Agreement, dated September 30, 2021, by and between Continental Stock Transfer & Trust Company and Monterey Bio (the “Trust Agreement”), allowing us to extend the Combination Period for an additional three (3) months, from October 5, 2022 to January 5, 2023 (the “Trust Amendment”), by depositing into the trust account the Extension Payment for the three-month extension, and thereafter to extend the Combination Period up to six (6) times by an additional month each time (or up to July 5, 2023) by depositing into the trust account $120,000 for each additional month extension;
3.Proposal No. 3 - The Director Proposal – a proposal to re-elect five directors to the Company’s board of directors, with each such director to serve until the second annual meeting of stockholders following this special meeting or until his or her successor is elected and qualified;
4.Proposal No. 4 - The Auditor Proposal – a proposal to ratify the selection by our Audit Committee of Marcum LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
| 2022-08-11 |
详情>>
业绩披露：
2022年中报每股收益-0.04美元,归母净利润-54.63万美元,同比去年增长-2184956%
|
| 2022-03-29 |
详情>>
业绩披露：
2021年年报每股收益-0.11美元,归母净利润-58.32万美元,同比去年增长-58222.7%
|